The latest biotech news

adc therapeutics nasdaq ipo aprea therapeutics

News and Trends 4 Oct 2019

ADC Therapeutics Cancels Nasdaq IPO Amidst Market Growth Fears

The Swiss biotech ADC Therapeutics has withdrawn its application for a €182M ($200M) Nasdaq IPO, citing adverse market conditions caused by global manufacturing slowdowns. ADC Therapeutics declined to comment on the specific market situation. Its withdrawal is likely due to slumps in European and US stock markets seen earlier this week caused by drops in […]

October 4, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 2 Oct 2019

RNA Therapies, Immunotherapies and Cancer Tests Showcased in Spain

Biotech companies around the world gathered in Barcelona, Spain, to present breakthroughs in cancer diagnostics and treatments such as cell therapies and cancer vaccines. Here’s our take on the most interesting offerings from the European crop. Barcelona is the home of Gaudi and Barcelona Football Club. Over the last few days, it was also the […]

October 2, 2019 - 6 minutesmins - By Jonathan Smith

News and Trends 30 Sep 2019

Update: Mixed Results for Adocia as Legal Fight with Eli Lilly Comes to a Close

Update (30/09/2019): A long legal battle between Adocia and Eli Lilly over a fast-acting insulin treatment development deal has finished with mixed results for Adocia. Eli Lilly has now paid €13M to Adocia, after the US Arbitration Association Panel supported Adocia’s claim last year. The payment consists of a milestone payment of €10.1M plus interest. […]

September 30, 2019 - 4 minutesmins - By Editorial Team

cancer immunotherapy stipe therapeutics novo holdings arix

News and Trends 30 Sep 2019

€20M Series A Launches Cancer Immunotherapy Biotech in Denmark

The Danish company STipe Therapeutics has been launched with a €20M Series A to develop immunotherapy drugs that sensitize the innate immune system against cancer. STipe Therapeutics was spun out from Aarhus University, Denmark, last year with a small grant, and has now completed its full launch with this Series A. The round was co-led […]

September 30, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 26 Sep 2019

Positive Phase III Results for Narcolepsy Drug with Low Cardiovascular Risk

The narcolepsy drug, developed by Irish company Jazz Pharmaceuticals, has a lower salt content than the current treatment Xyrem, making it more suitable for patients at risk of cardiovascular disease. In a 200-patient phase III trial that finished in July, Jazz Pharmaceutical’s experimental drug was able to reduce the number of cataplexy attacks and the […]

September 26, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 25 Sep 2019

Danish Smallpox Vaccine Gets FDA Approval to Fight Bioterrorism

A vaccine developed by the Danish company Bavarian Nordic has received FDA approval to prevent infections by monkeypox, as well as protect against the threat of a smallpox bioterror attack. This approval makes Bavarian Nordic’s vaccine the only approved vaccine in the world for preventing monkeypox, a rare viral infection that is similar to smallpox […]

September 25, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 25 Sep 2019

German Biotech Will Develop Carbohydrate-Targeting Cancer Treatments

The German startup Tacalyx has raised €7M in a seed round to fund the preclinical development of first-in-class carbohydrate-targeting antibody drugs for the treatment of cancer. The round was co-led by the Germany-based Boehringer Ingelheim Venture Fund and the French VC firm Kurma Partners. Tacalyx will use the money to generate a lead candidate antibody […]

September 25, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 24 Sep 2019

Rare Metal Could Turbocharge Cancer Light Therapies

A team of European and Chinese researchers has developed a light-activated cancer therapy containing the rare metal iridium that could potentially activate the immune system against cancer. In a study published in Nature Chemistry, the drug killed multiple types of cancer cells in a dish when activated by red light. The study also revealed that […]

September 24, 2019 - 2 minutesmins - By Jonathan Smith

mallinckrodt burns treatment stratagraft

News and Trends 24 Sep 2019

Lab-Grown Skin as Good as Skin Grafts for Burns at Phase III

Mallinckrodt’s treatment made of artificial skin tissue called Stratagraft closed over 80% of second-degree burn wounds in a phase III trial, matching the effectiveness of skin grafts. Mallinckrodt recruited 71 patients with second-degree burns who were eligible for skin grafts into the trial. Each patient received the artificial skin graft on some areas of burned […]

September 24, 2019 - 2 minutesmins - By Jonathan Smith

novo nordisk type 2 diabetes semaglutide

News and Trends 23 Sep 2019

FDA Greenlights First Oral Version of Novo Nordisk’s Type 2 Diabetes Drug

The first oral drug for type 2 diabetes belonging to the class of GLP-1 agonists, developed by Novo Nordisk, has got the go-ahead from the FDA. The Danish company is known for its blockbuster injectable drug in the same class — liraglutide — that is now one of the most highly prescribed drugs in the […]

September 23, 2019 - 2 minutesmins - By Jonathan Smith

breathomix breath diagnostics lung cancer

News and Trends 19 Sep 2019

Dutch ‘Electronic Nose’ Predicts Cancer Immunotherapy Success

A diagnostic device measuring chemicals in the breath, developed by the Dutch company Breathomix, was able to identify lung cancer patients that wouldn’t respond to cancer immunotherapy with unprecedented accuracy. Researchers at the University of Amsterdam tested the device on 143 lung cancer patients, who were going to receive immunotherapy in the form of the […]

September 19, 2019 - 2 minutesmins - By Jonathan Smith

brain cancer glioblastoma divide and conquer

News and Trends 18 Sep 2019

UK Cancer Biotech Raises €11M Series A to Break Up Brain Tumors

The Cambridge-based company Divide and Conquer has raised €11.3M (£10M) to develop a treatment that breaks up glioblastoma tumors, exposing them to attack by chemotherapy and radiotherapy. With this Series A round, funded by the UK VC firm Medicxi, Divide and Conquer has exited stealth mode a year after its foundation. The company will use […]

September 18, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

ADC Therapeutics Cancels Nasdaq IPO Amidst Market Growth Fears

RNA Therapies, Immunotherapies and Cancer Tests Showcased in Spain

Update: Mixed Results for Adocia as Legal Fight with Eli Lilly Comes to a Close

€20M Series A Launches Cancer Immunotherapy Biotech in Denmark

Positive Phase III Results for Narcolepsy Drug with Low Cardiovascular Risk

Danish Smallpox Vaccine Gets FDA Approval to Fight Bioterrorism

German Biotech Will Develop Carbohydrate-Targeting Cancer Treatments

Rare Metal Could Turbocharge Cancer Light Therapies

Lab-Grown Skin as Good as Skin Grafts for Burns at Phase III

FDA Greenlights First Oral Version of Novo Nordisk’s Type 2 Diabetes Drug

Dutch ‘Electronic Nose’ Predicts Cancer Immunotherapy Success

UK Cancer Biotech Raises €11M Series A to Break Up Brain Tumors

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!